true
--09-30
2026
Q1
0001314052
0001314052
2025-10-01
2025-12-31
0001314052
2026-02-09
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
xbrli:pure
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
10-Q/A
(Mark One)
AMENDMENT NO. 1
TO
☒
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended: December 31,
2025
☐ TRANSITION
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from _____to _____
Commission File Number: 001-37606
ANAVEX
LIFE SCIENCES CORP.
(Exact name of registrant as specified
in its charter)
| Nevada |
98-0608404 |
| (State or other jurisdiction of |
(IRS Employer |
| incorporation or organization) |
Identification No.) |
630 5th Avenue, 20th Floor, New York, NY USA
10111
(Address of principal executive offices) (Zip
Code)
1-844-689-3939
(Registrant’s telephone number,
including area code)
Securities Registered Pursuant to Section 12(b)
of the Act:
| Title of Each Class |
|
Trading Symbol |
|
Name of Each Exchange on Which Registered |
| Common Stock Par Value $0.001 |
|
AVXL |
|
NASDAQ Stock Market LLC |
Indicate by check mark whether the registrant (1)
has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months
(or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements
for the past 90 days.
☒ Yes ☐
No
Indicate by check mark whether the registrant has
submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of
this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
☒
Yes ☐ No
Indicate by check mark whether the registrant is a
large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See
the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and
“emerging growth company” in Rule 12b-2 of the Exchange Act.
| Large accelerated filer |
☒ |
|
Accelerated filer |
☐ |
| Non-accelerated filer |
☐ |
|
Smaller reporting company |
☐ |
| |
|
|
Emerging growth company |
☐ |
If an emerging growth company, indicate by check mark
if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act
☐
Indicate by check mark whether the registrant is a
shell company (as defined in Rule 12b-2 of the Exchange Act).
☐
Yes ☒ No
Indicate the number of shares outstanding of each
of the issuer’s classes of Common Stock, as of the latest practicable date: 92,671,758 shares of Common Stock outstanding as of
February 9, 2026.
As used in this Amendment (defined below), the terms
“we,” “us,” “our,” “Company” and “Anavex” mean Anavex Life Sciences Corp.,
unless the context clearly requires otherwise.
EXPLANATORY NOTE
As previously disclosed in a Current Report on
Form 8-K, filed with the Securities and Exchange Commission (“SEC”) on May 6, 2026, on April 30, 2026, a special
committee (the “Special Committee”) composed of independent directors of the Board of Directors of the Company (the
“Board”) terminated the employment of the Company’s former Chief Executive Officer (“CEO”) for Cause
(as defined in the Employment Agreement, dated as of June 27, 2013, between the Company and its former CEO, as amended and
restated), effective immediately for, among other things, conduct that the Special Committee believed was inconsistent with Company
policy. As a result of the review by the Special Committee, management, in consultation with the Audit Committee of the Board (the
“Audit Committee”), concluded that there was a material weakness in internal control over financial reporting that
existed at September 30, 2025. Accordingly, the Company’s internal control over financial reporting as of December 31, 2025,
as reported in its Quarterly Report on Form 10-Q for the fiscal quarter ended December 31, 2025 (the “Original Form
10-Q”) were not effective. In addition, the Company’s disclosure controls and procedures were not effective as of
December 31, 2025, due to the material weakness in internal control over financial reporting as described above.
The reassessment of the effectiveness of the Company’s disclosure
controls and procedures and its internal control over financial reporting described above did not result in any misstatement in
the Company’s previously issued condensed consolidated interim financial statements for the quarterly period ended December 31,
2025. As a result, the Company is not restating its condensed consolidated interim financial statements in this Amendment No. 1 (this
“Amendment”) to the Original Form 10-Q.
The Company is filing this Amendment to amend the
following:
| ● | Item
4. “Controls and Procedures” was amended to reflect ineffective disclosure controls and procedures and internal
control over financial reporting as of December 31, 2025 as a result of the material weakness related to entity-level control deficiencies
as described in the Company’s Form 10-K/A for the fiscal year ended September 30, 2025, (the “2025 Form 10-K/A”) filed
with the SEC on August 28, 2026. |
| ● | Item
6. “Exhibits” of the Original Form 10-Q is amended and restated to reflect
the new certifications referenced below. |
This
Amendment also includes the following exhibits to replace exhibits previously filed:
| |
● |
new currently dated certifications (as required by Rule 12b-15 under the Securities Exchange Act of 1934, as amended), by the Company’s principal executive officer and principal financial officer. |
Except as described in this Explanatory Note, this Amendment does not amend, modify
or update disclosures included in the Original Form 10-Q, nor does it reflect events occurring after the filing of the Original Form 10-Q.
Among other things, business-related disclosures, risk factors and forward-looking statements made in the Original Form 10-Q have
not been revised to reflect events that occurred or facts that became known to the Company after the filing of the Original Form 10-Q,
and any such statements should be read in their historical context. Accordingly, this Amendment should be read in conjunction with the
Company’s filings with the SEC that were made subsequent to the filing of the Original Form 10-Q and this Amendment.
TABLE OF CONTENTS
| PART I |
4 |
| ITEM 4. CONTROLS AND PROCEDURES |
4 |
| ITEM 6. EXHIBITS |
5 |
| SIGNATURES |
6 |
PART I
ITEM 4. CONTROLS AND PROCEDURES
Disclosure Controls and
Procedures
As previously disclosed in a Current Report on Form
8-K, filed with the Securities and Exchange Commission (“SEC”) on May 6, 2026, on April 30, 2026, a special committee (the
“Special Committee”) composed of independent directors of our Board of Directors (the “Board”) terminated the
employment of our former Chief Executive Officer (“CEO”) for Cause (as defined in the Employment Agreement, dated as of June
27, 2013, between us and our former CEO, as amended and restated) effective immediately for, among other things, conduct that the Special
Committee believed was inconsistent with Company policy.
As a result of the review by the Special Committee,
management, in consultation with the Audit Committee of the Board, re-assessed the effectiveness of our disclosure controls and procedures
and our internal control over financial reporting as of December 31, 2025. This re-evaluation of our disclosure controls and procedures
and our internal control over financial reporting in this 10-Q/A considers the circumstances in effect at December 31, 2025, prior to
the termination of our former CEO.
Quarterly Evaluation of Disclosure Controls and Procedures (Amended
and Restated)
We maintain disclosure controls and procedures (as defined in Rules 13a-15(e) and
15d-15(e) promulgated under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) that are designed to
provide reasonable assurance that material information required to be disclosed in our periodic reports filed under the Exchange Act is
recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms and to provide reasonable
assurance that such information is accumulated and communicated to our Principal Executive Officer and our Principal Financial Officer,
to allow timely decisions regarding required disclosure.
We carried out an evaluation, under the supervision and with the participation
of our management, including our Principal Executive Officer and our Principal Financial Officer, of the effectiveness of the design and
operation of our disclosure controls and procedures as of December 31, 2025. As previously disclosed in the Form 10-K/A for the fiscal
year ended September 30, 2025, filed with the SEC on August 28, 2026 (the “2025 Form 10-K/A”), management identified a material
weakness in our internal control over financial reporting. Because this material weakness had not been fully remediated as of December
31, 2025, management concluded that the Company’s disclosure controls and procedures were not effective as of that date.
Notwithstanding the material weakness described in
the Form 10-K/A, management has concluded that the financial statements included in the Original Form 10-Q are fairly presented, in all
material respects, in accordance with U.S. GAAP.
Changes in Internal
Control over Financial Reporting
Other than as described above, during the quarter ended December 31, 2025, there
were no changes in our internal control over financial reporting that have materially affected, or are reasonably likely to materially
affect, our internal control over financial reporting. The material weakness described in the 2025 Form 10-K/A was identified subsequent
to the end of the quarter, and therefore no remediation activities had been designed or implemented as of December 31, 2025. Following
the identification of the material weakness, management began developing a remediation plan, as described in the 2025 Form 10-K/A.
ITEM 6. EXHIBITS
Exhibit
Number |
Description |
| (3)
|
Articles
of Incorporation and Bylaws |
| 3.1
|
Articles of Incorporation, as amended (incorporated by reference to Exhibit 3.1 to our Annual Report on Form 10-K for the year ended September 30, 2021 filed on November 24, 2021) |
| 3.2 |
Amended and Restated Bylaws (incorporated by reference to Exhibit 3.1 to our Current Report on Form 8-K filed on April 14, 2023) |
| (31)
|
Rule
13a-14(a)/15(d)-14(a)Certifications |
| 31.1* |
Certification of Terrie Kellmeyer, Ph.D. |
| 31.2* |
Certification of Sandra Boenisch |
| (32)
|
Section
1350 Certifications |
| 32.1** |
Certification of Terrie Kellmeyer, Ph.D. and Sandra Boenisch. |
| (101) |
XBRL |
| 101.INS* |
XBRL
INSTANCE DOCUMENT |
| 101.SCH* |
XBRL
TAXONOMY EXTENSION SCHEMA |
| 101.CAL* |
XBRL
TAXONOMY EXTENSION CALCULATION LINKBASE |
| 101.DEF* |
XBRL
TAXONOMY EXTENSION DEFINITION LINKBASE |
| 101.LAB* |
XBRL
TAXONOMY EXTENSION LABEL LINKBASE |
| 101.PRE* |
XBRL
TAXONOMY EXTENSION PRESENTATION LINKBASE |
* Filed herewith.
** Furnished herewith.
SIGNATURES
Pursuant to the requirements of the Securities Exchange
Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
ANAVEX LIFE SCIENCES CORP.
| /s/ Terrie Kellmeyer, Ph.D. |
|
| |
|
| Terrie Kellmeyer, Ph.D. |
|
| Interim Chief Executive Officer |
|
| (Principal Executive Officer) |
|
| Date: August 28, 2026 |
|
| /s/Sandra Boenisch |
|
| |
|
| Sandra Boenisch, CPA, CGA |
|
| Principal Financial Officer |
|
| (Principal Financial and Accounting Officer) |
|
| Date: August 28, 2026 |
|
6
